Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma

ConclusionPazopanib has activity in Pheo/PGL requiring more study; optimal alpha- and beta-blockade are imperative pre-therapy in patients with secretory tumors, as risk of hypertension and cardiomyopathy are potentially life threatening.

Source: Endocrine - July 6, 2017 Category: Endocrinology Source Type: research